<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01207089</url>
  </required_header>
  <id_info>
    <org_study_id>D2350C00010</org_study_id>
    <nct_id>NCT01207089</nct_id>
  </id_info>
  <brief_title>To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Administration of AZD8329</brief_title>
  <acronym>AZ8329</acronym>
  <official_title>A Phase I, Single Centre, Single-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD8329 After Administration of Multiple Ascending Doses in Abdominally Obese But Otherwise Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety, tolerability, pharmacokinetics and
      pharmacodynamics of AZD8329 following multiple ascending dose administrations in in
      overweight to obese but otherwise healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, Single Centre, Single-blind, Randomised, Placebo-controlled, Parallel-group Study
      to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of oral AZD8329
      after Administration of Multiple Ascending Doses in Abdominally Obese but otherwise Healthy
      Male Subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety variables (adverse events).</measure>
    <time_frame>Adverse events day -1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety variables (adverse events).</measure>
    <time_frame>Adverse events will colletected entire study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety variables (clinical laboratory assessments).</measure>
    <time_frame>Clinical labs day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety variables (clinical laboratory assessments).</measure>
    <time_frame>Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety variables (clinical laboratory assessments).</measure>
    <time_frame>Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety variables (clinical laboratory assessments).</measure>
    <time_frame>Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety variables (clinical laboratory assessments).</measure>
    <time_frame>Clinical labs at follow up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety variables (adverse events)</measure>
    <time_frame>Adverse events will colletected entire study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety variables (vital signs)</measure>
    <time_frame>vital signs every hour during day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety variables (physical examination)</measure>
    <time_frame>performed at screening</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety variables (vital signs)</measure>
    <time_frame>Vital Signs every hr during day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety variables (physical examination)</measure>
    <time_frame>Performed at follow up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety variables (telemetry)</measure>
    <time_frame>telemetry for 24hr. post dose day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety variables (telemetry)</measure>
    <time_frame>telemetry for 24hr. post dose day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety variables (digital electrocardiograms (dECGs))</measure>
    <time_frame>dECG during 5min, 13 times 24 hr after dose day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety variables (digital electrocardiograms (dECGs))</measure>
    <time_frame>dECG during 5min, 13 times 24 hr after dose day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety variables (safety 12-lead paper electrocardiograms (pECG))</measure>
    <time_frame>pECG at screening</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety variables (safety 12-lead paper electrocardiograms (pECG))</measure>
    <time_frame>pECG at follow up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety variables (clinical laboratory assessments).</measure>
    <time_frame>clinical labs at screening</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety variables (clinical laboratory assessments).</measure>
    <time_frame>clinical labs day -3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Plasma and urine concentrations of AZD8329 and plasma and urine pharmacokinetics parameters</measure>
    <time_frame>Information will be collected during day -1, day 1, 2, 3 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic 11-βHSD1 enzyme activity in adipose tissue</measure>
    <time_frame>Information will be collected from the time of day -1 throuout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic 11-βHSD1 enzyme activity in the liver by measuring prednisolone generation</measure>
    <time_frame>Information will be collected from day -1 to follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effect on insulin after multiple doses of AZD8329</measure>
    <time_frame>Information will be collected from day -2 to follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effect on glucose after multiple doses of AZD8329</measure>
    <time_frame>Information will be collected from day -2 to follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effect on lipid variables after multiple doses of AZD8329</measure>
    <time_frame>Information will be collected from day -2 to follow up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Overweight</condition>
  <condition>Healthy</condition>
  <condition>Male</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD8329</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD8329</intervention_name>
    <description>AZD8329 Oral Solution 20mg/ml</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo AZD8329 Oral Solution</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a body mass index (BMI) between 27 and 35 kg/m2 and a waist circumference greater
             than or equal to 102cm.

          -  Provision of signed and dated, written informed consent prior to any study specific
             procedures

          -  Healthy male subjects aged =20 to =50 years with suitable veins for cannulation or
             repeated venepuncture

        Exclusion Criteria:

          -  History of any clinically significant disease or disorder which, in the opinion of the
             investigator, may either put the subject at risk because of participation in the
             study, or influence the results or the subject's ability to participate.

          -  Fasting serum (S)-glucose =7.0 mmol/L or non-fasting S-glucose =11.1 mmol/L at
             screening.

          -  Any eating disorder or actively attempting to loose weight within 3 months prior to
             enrolment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Jan Eriksson</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Mirjana Kujacic</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. James Ritter</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Drug Research Unit at Guy's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2010</study_first_submitted>
  <study_first_submitted_qc>September 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2010</study_first_posted>
  <last_update_submitted>May 9, 2011</last_update_submitted>
  <last_update_submitted_qc>May 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>AstraZeneca</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>PK</keyword>
  <keyword>healthy</keyword>
  <keyword>overweight</keyword>
  <keyword>obese</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

